Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer

A month after the US FDA granted approval of Celltrion's biosimilar infliximab, another South Korean firm, Samsung Bioepis, is rapidly progressing its diverse pipeline and is seeking an entry into the US market through an approval filing for its biosimilar version of the anti-inflammatory antibody. The product is already available in South Korea and recently won a green light in Europe.